Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective initial steroid regimen in idiopathic steroid-sensitive nephrotic syndrome based on time to first remission
KCT0007771Phase 4Not yet recruiting
- Sponsor
- Child Cancer & Rare Disease Project
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of prednisolone in idiopathic steroid-sensitive nephrotic syndrome (SSNS), sponsored by Child Cancer & Rare Disease Project. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
idiopathic steroid-sensitive nephrotic syndrome (SSNS)
Beyond the preview
Go deeper on KCT0007771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007771.